Drug Profile
Epetirimod
Alternative Names: 851A; 851B; epetirimod esylate; R851; S-30563; S-30563-35-65; TAK-851Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator 3M Pharmaceuticals
- Developer Takeda
- Class Antineoplastics; Antivirals
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cervical dysplasia; Human papillomavirus infections
Most Recent Events
- 19 Nov 2013 Profile reviewed - prompted by Wendy's request (via Indu) re CTP18853. Matched R-851 with Epetirimod and requested changes in Thes; only two terminated trials on CT.gov, Takeda's pipeline of October 31, 2013 (TAK-851 no listed); added gel formulation
- 01 Feb 2009 Discontinued - Phase-II for Cervical dysplasia in Canada (Topical)
- 01 Feb 2009 Discontinued - Phase-II for Cervical dysplasia in European Union (Topical)